Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
Eiger BioPharmaceuticals, Inc. (the
Company) is furnishing the investor
presentationslides attached as Exhibit 99.1to this Current Report
on Form 8-K, which the Company may use from time to time in
conversations with investors and analysts.
The information in this report is being furnished to Item7.01 and
shall not be deemed to be filed for purposes of Section17 of the
Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to
the liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.
Item9.01 |
Financial Statements and Exhibits. |
(d) |
Exhibits |
Reference is made to the Exhibit Index included with this Current
Report on Form 8-K.
2
About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Recent Trading Information
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) closed its last trading session up +0.20 at 12.45 with 63,192 shares trading hands.
